Glycyl tRNA Synthetase Recombinant Protein | GARS recombinant protein

Recombinant Glycyl tRNA Synthetase (GARS)

Cat. Num. AAA2030433

• Gene Names: GARS; HMN5; CMT2D; DSMAV; GlyRS; SMAD1
• Applications: SDS-Page, Western Blot, ELISA, Immunoprecipitation
• Purity: >90%
• Synonyms: Glycyl tRNA Synthetase; Recombinant Glycyl tRNA Synthetase (GARS); GARS recombinant protein

• Host: Host: E Coli; Source: Prokaryotic expression
• Purity/Purification: >90%
• Form/Format: Supplied as lyophilized form in PBS, pH7.4, containing 5% trehalose, 0.01% sarcosyl.
• Sequence: The target protein is fused with two N-terminal Tags, His-tag and T7-tag, its sequence is listed below.; VEEV VPNVIEPSFG LGRIMYTVFE HTFHVREGDEQRTFFSFPAV VAPFKCSVLP LSQNQEFMPF VKELSEALTR HGVSHKVDDSSGSIGRRYAR TDEIGVAFGV TIDFDTVNKT PHTATLRDRD SMRQIRAEISELPSIVQDLA NGNITWADVE ARYPLFEGQE TGKKE
• Sequence Length: 739

• Applicable Applications for GARS recombinant protein: SDS-PAGE, Western Blot (WB), ELISA (EIA), Immunoprecipitation (IP)
• Predicted Molecular Mass: 22.7kDa
• Accurate Molecular Mass (KD): 23kDa
• Endotoxin: <1.0EU per 1ug (determined by the LAL method)
• Expression System: Prokaryotic expression
• Tag: two N-terminal Tags, His-tag and S-tag
• Organism Species: Homo sapiens (Human)
• Fragment: Val567~Glu735
• Usage: Reconstitute in sterile PBS, pH7.2-pH7.4.
• Preparation and Storage: Storage: Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months.; Stability Test: The thermal stability is described by the loss rate of the targetprotein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 degree C for 48h, and no obvious degradation andprecipitation were observed. The loss of this protein is less than 5% within the expiration date under appropriate storage condition.

Sequence Information

SDS-Page

NCBI and Uniprot Product Information

• NCBI GI #: 1311463
• NCBI GeneID: 2617
• Molecular Weight: 83,166 Da
• NCBI Official Full Name: glycyl tRNA synthetase
• NCBI Official Synonym Full Names: glycyl-tRNA synthetase
• NCBI Official Symbol: GARS
• NCBI Official Synonym Symbols: HMN5; CMT2D; DSMAV; GlyRS; SMAD1
• NCBI Protein Information: glycine--tRNA ligase
• UniProt Protein Name: Glycine--tRNA ligase
• Protein Family: Glycine--tRNA ligase
• UniProt Gene Name: GARS
• UniProt Synonym Gene Names: AP-4-A synthetase; GlyRS
• UniProt Entry Name: SYG_HUMAN

NCBI Description

This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis. [provided by RefSeq, Jul 2008]

Uniprot Description

GARS: Catalyzes the attachment of glycine to tRNA(Gly). Is also able produce diadenosine tetraphosphate (Ap4A), a universal pleiotropic signaling molecule needed for cell regulation pathways, by direct condensation of 2 ATPs. Defects in GARS are the cause of Charcot-Marie-Tooth disease type 2D (CMT2D). CMT2D is a form of Charcot- Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2D is characterized by a more severe phenotype in the upper extremities (severe weakness and atrophy, absence of tendon reflexes) than in the lower limbs. CMT2D inheritance is autosomal dominant. Defects in GARS are a cause of distal hereditary motor neuronopathy type 5A (HMN5A); also known as distal hereditary motor neuropathy type V (DSMAV). A disorder characterized by distal muscular atrophy mainly affecting the upper extremities, in contrast to other distal motor neuronopathies. These constitute a heterogeneous group of neuromuscular diseases caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. Belongs to the class-II aminoacyl-tRNA synthetase family.

Protein type: Ligase; EC 6.1.1.14; Translation; Mitochondrial

Chromosomal Location of Human Ortholog: 7p15

Cellular Component: nucleoplasm; mitochondrial matrix; cytoplasm; cytosol; secretory granule

Molecular Function: protein dimerization activity; glycine-tRNA ligase activity; ATP binding

Biological Process: tRNA aminoacylation for protein translation; glycyl-tRNA aminoacylation; gene expression; diadenosine tetraphosphate biosynthetic process

Disease: Neuronopathy, Distal Hereditary Motor, Type Va; Charcot-marie-tooth Disease, Axonal, Type 2d